Sermonix Pharmaceuticals

Sermonix Pharmaceuticals is a biopharmaceutical company that was founded in 2014 with a focus on developing targeted therapeutics to treat ESR1-mutated metastatic breast and gynecological cancers. The company's slogan, "Passion and purpose in women’s oncology," reflects its commitment to addressing critical unmet medical needs in women's health.

Under the leadership of founder David Portman, MD, a renowned clinical researcher and expert in women's health, Sermonix Pharmaceuticals is conducting ELAINE studies to evaluate an investigational oral drug, lasofoxifene, a novel targeted endocrine agent, in women and men with locally advanced or metastatic estrogen receptor-positive/human epidermal growth factor 2-negative (ER+/HER2-) breast cancer harboring an ESR1 mutation(s).

The company recently secured a significant $40.00M Series A investment on 15 November 2021 from Perceptive Advisors, a notable player in the investment landscape. This injection of funds will likely bolster Sermonix Pharmaceuticals' research efforts and propel the development of potentially groundbreaking treatments in the field of women's oncology.

With its clear vision, experienced leadership, and endorsement from notable investors, Sermonix Pharmaceuticals is poised to make a substantial impact in the biopharmaceutical industry, offering hope to patients and potential returns to investors.